Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/01/22
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 05/19/20
End: 12/30/25
Due: 12/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma | NCT06194695 | Ze-yang Ding, MD | user2@example.com | None | 2022-02-01 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT05713994 | Ze-yang Ding, MD | user2@example.com | None | 2020-05-19 | 2025-12-30 | 2026-12-30 | - | - | 2025-07-14 |